Cargando…

The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies

Cardiomyopathies (CMPs) are a heterogeneous group of myocardial diseases accountable for the majority of cases of heart failure (HF) and/or sudden cardiac death (SCD) worldwide. With the recent advances in genomics, the original classification of CMPs on the basis of morphological and functional cri...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagiatakis, Christina, Di Mauro, Vittoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395924/
https://www.ncbi.nlm.nih.gov/pubmed/34445422
http://dx.doi.org/10.3390/ijms22168721
_version_ 1783744281680281600
author Pagiatakis, Christina
Di Mauro, Vittoria
author_facet Pagiatakis, Christina
Di Mauro, Vittoria
author_sort Pagiatakis, Christina
collection PubMed
description Cardiomyopathies (CMPs) are a heterogeneous group of myocardial diseases accountable for the majority of cases of heart failure (HF) and/or sudden cardiac death (SCD) worldwide. With the recent advances in genomics, the original classification of CMPs on the basis of morphological and functional criteria (dilated (DCM), hypertrophic (HCM), restrictive (RCM), and arrhythmogenic ventricular cardiomyopathy (AVC)) was further refined into genetic (inherited or familial) and acquired (non-inherited or secondary) forms. Despite substantial progress in the identification of novel CMP-associated genetic variations, as well as improved clinical recognition diagnoses, the functional consequences of these mutations and the exact details of the signaling pathways leading to hypertrophy, dilation, and/or contractile impairment remain elusive. To date, global research has mainly focused on the genetic factors underlying CMP pathogenesis. However, growing evidence shows that alterations in molecular mediators associated with the diagnosis of CMPs are not always correlated with genetic mutations, suggesting that additional mechanisms, such as epigenetics, may play a role in the onset or progression of CMPs. This review summarizes published findings of inherited CMPs with a specific focus on the potential role of epigenetic mechanisms in regulating these cardiac disorders.
format Online
Article
Text
id pubmed-8395924
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83959242021-08-28 The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies Pagiatakis, Christina Di Mauro, Vittoria Int J Mol Sci Review Cardiomyopathies (CMPs) are a heterogeneous group of myocardial diseases accountable for the majority of cases of heart failure (HF) and/or sudden cardiac death (SCD) worldwide. With the recent advances in genomics, the original classification of CMPs on the basis of morphological and functional criteria (dilated (DCM), hypertrophic (HCM), restrictive (RCM), and arrhythmogenic ventricular cardiomyopathy (AVC)) was further refined into genetic (inherited or familial) and acquired (non-inherited or secondary) forms. Despite substantial progress in the identification of novel CMP-associated genetic variations, as well as improved clinical recognition diagnoses, the functional consequences of these mutations and the exact details of the signaling pathways leading to hypertrophy, dilation, and/or contractile impairment remain elusive. To date, global research has mainly focused on the genetic factors underlying CMP pathogenesis. However, growing evidence shows that alterations in molecular mediators associated with the diagnosis of CMPs are not always correlated with genetic mutations, suggesting that additional mechanisms, such as epigenetics, may play a role in the onset or progression of CMPs. This review summarizes published findings of inherited CMPs with a specific focus on the potential role of epigenetic mechanisms in regulating these cardiac disorders. MDPI 2021-08-13 /pmc/articles/PMC8395924/ /pubmed/34445422 http://dx.doi.org/10.3390/ijms22168721 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pagiatakis, Christina
Di Mauro, Vittoria
The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies
title The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies
title_full The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies
title_fullStr The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies
title_full_unstemmed The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies
title_short The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies
title_sort emerging role of epigenetics in therapeutic targeting of cardiomyopathies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395924/
https://www.ncbi.nlm.nih.gov/pubmed/34445422
http://dx.doi.org/10.3390/ijms22168721
work_keys_str_mv AT pagiatakischristina theemergingroleofepigeneticsintherapeutictargetingofcardiomyopathies
AT dimaurovittoria theemergingroleofepigeneticsintherapeutictargetingofcardiomyopathies
AT pagiatakischristina emergingroleofepigeneticsintherapeutictargetingofcardiomyopathies
AT dimaurovittoria emergingroleofepigeneticsintherapeutictargetingofcardiomyopathies